Alicia Morgans: Hi. I am so excited to talk today with Dr. Cora Sternberg, who is a Professor of Medicine at Weill Cornell and the Clinical Director of the Israel Englander Institute for Precision Medicine also at Weill Cornell. Thank you so much for being here. Cora Sternberg: Thank you. It’s a pleasure to be […]
Charles Ryan: Hello from PCF 2019. It’s a pleasure to be talking to Joaquin Mateo, who is a Principal Investigator and Translational Scientist at the Vall d’Hebron hospital in Barcelona. Joaquin Mateo: Yeah. Charles Ryan: You’ve been involved in really the many pivotal studies that are reporting and ongoing with PARP inhibitors in prostate cancer. […]
Charles Ryan: Hello from PCF 2019. I’m delighted to be joined by Dr. Stacey Kenfield, a colleague from UCSF where she is an Associate Professor in the Department of Urology and is the Helen Diller Family Professor of Population Science for Urologic Cancer. And you are an expert on lifestyle, exercise, nutrition and their impact […]
Alicia Morgans: Hi. I am so thrilled to have here with me today Dr. Scott Tagawa, Professor of Medicine at Weill Cornell University, New York. Thank you so much for being here. Scott Tagawa: Great to be here. Thanks for the invite. Alicia Morgans: Course. I wanted to really pick your brain about some of […]
Charles Ryan: Hello from PCF 2019. I’m joined by Dan Spratt, Associate Professor, Radiation Oncologist from the University of Michigan. You got a lot going on, my friend, and you really made a splash a couple of weeks ago presenting an update of the Shipley data from the RTOG studies, which was a really important […]
Introduction: Multiple studies have reported genetic associations with prognostic outcomes of urinary bladder cancer. However, the lack of replication of these associations prohibits establishing further evidence-based research directions. Moreover, there is a lack of independent bladder cancer patient samples that contain prognostic measures, making genetic replication analyses even more challenging. Materials and Methods: We have […]
There is growing interest in a bladder preservation approach using chemoradiation therapy with transurethral resection of bladder tumor (TURBT), i.e., combined modality treatment (CMT), for muscle-invasive bladder cancer (MIBC). We have initiated a pilot study to determine feasibility of conducting a larger-scale clinical trial comparing CMT to radical cystectomy (RC) in patients with MIBC. Here […]
The neutrophil-to-lymphocyte ratio (NLR) is an attractive marker because it is derived from routine bloodwork. NLR has shown promise as a prognostic factor in muscle invasive bladder cancer (MIBC) but its value in patients receiving neoadjuvant chemotherapy (NAC) before radical cystectomy (RC) is not yet established. Since NLR is related to an oncogenic environment and […]
To investigate the predictive value of common preoperative laboratory variables in patients undergoing bilateral inguinal lymph node dissection surgery for penile squamous cell carcinoma. We retrospectively analyzed the records of 228 patients who had bilateral inguinal lymph node dissection for penile squamous cell carcinoma to assess the following clinical factors: preoperative laboratory measurements, white blood […]
The aim of this study is to analyse the of expression levels of microRNA-200 family members in patients with metastatic clear cell renal cell carcinoma (ccRCC). Analysis of microRNA expression was performed on 23 paired DNA samples extracted from kidney tumour tissue and the surrounding normal renal parenchyma. MicroRna-200c was found to have significantly lower […]
